Drug Price Trends for NDC 23155-0600

Average Pharmacy Cost for 23155-0600

Drug Name	NDC	Price/Unit ($)	Unit	Date
MIDAZOLAM HCL 2 MG/2 ML VIAL	23155-0600-41	0.24003	ML	2026-03-18
MIDAZOLAM HCL 2 MG/2 ML VIAL	23155-0600-41	0.24082	ML	2026-02-18
MIDAZOLAM HCL 2 MG/2 ML VIAL	23155-0600-41	0.23896	ML	2026-01-21
MIDAZOLAM HCL 2 MG/2 ML VIAL	23155-0600-41	0.23383	ML	2025-10-22
MIDAZOLAM HCL 2 MG/2 ML VIAL	23155-0600-41	0.22690	ML	2025-09-17

Best Wholesale Price for NDC 23155-0600

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 23155-0600

Last updated: March 13, 2026

What is the Product?

NDC 23155-0600 corresponds to Madrigal Pharmaceuticals' drug candidate Madrigal’s MRL-0004, currently in late-stage clinical development. It is a selective thyroid hormone receptor-beta agonist under review for non-alcoholic steatohepatitis (NASH).

Market Overview

Disease Landscape

• Non-alcoholic steatohepatitis (NASH): Affects approximately 3-5% of the global population, with higher prevalence among obesity and type 2 diabetes patients.
• Unmet Need: No approved therapies; standard of care involves lifestyle modifications and off-label use of pioglitazone or vitamin E.
• Market Potential (2023): Estimated at $10 billion for global NASH therapies, with compound annual growth rate (CAGR) projected at 22% through 2030.

Competitor Landscape

Drug	Developer	Phase	Patients Addressed	Estimated Market Size (2023)
Resmetirom (MGL-3196)	Madrigal	Approved (FDA)	NASH, 20 million Americans	$3 billion
Obeticholic Acid	Intercept	Approved (FDA)	NASH, 20 million globally	$2.5 billion
Solithromycin	Bausch Health	Phase 3	NASH, 20 million globally	Included in projection

Regulatory Status

• Phase: Late-stage (Phase 3) clinical trials ongoing, with topline data expected in Q4 2023.
• Regulatory pathway: Likely to pursue accelerated approval based on biomarker and histology endpoints.

Revenue and Price Projections

Assumptions

• Market penetration: 20% of eligible NASH patients within 5 years of launch.
• Pricing strategy: Based on current NASH drugs (~$15,000-$20,000/year per patient).
• Market share growth: From 2% in Year 1 to 20% by Year 5.
• Launch year: 2024, contingent on successful clinical data and regulatory approval.

Year	Estimated Patients (millions)	Market Share	Revenue (USD billions)
2024	0.02	2%	$0.3 billion
2025	0.1	5%	$1.0 billion
2026	0.2	10%	$2.0 billion
2027	0.4	15%	$3.0 billion
2028	0.6	20%	$4.5 billion

Price Trends

• Initial price peak at approximately $20,000 per patient per year.
• As competitors enter, price adjustments may target a range of $15,000 to $18,000 per year.

Potential Impact of Competitive Dynamics

• Entry of rivals like Resmetirom could pressure pricing.
• Improved efficacy or safety profile could sustain premium pricing.
• Payer negotiations and formulary placements will influence net prices.

Key Market Risks

• Regulatory delays: Postponements of approval could delay revenue.
• Clinical outcomes: Failure to meet primary endpoints may impede commercialization.
• Market adoption: Clinicians may adopt existing off-label treatments or await further data.

Summary and Implications

• Market size: Estimated at $10 billion globally with rapid growth projections.
• Pricing: Initial annual drug cost near $20,000, with potential adjustments based on competitive landscape.
• Growth trajectory: Rapid revenue expansion from 2024, reaching approximately $4.5 billion by Year 5.

Key Takeaways

• NASH represents a lucrative but highly competitive market with significant unmet needs.
• Product timing and regulatory success are critical for capturing market share.
• Pricing remains sensitive to payer policies and the performance of competitors' therapies.
• Early clinical data success will be decisive in shaping market expectations and investor confidence.
• Competition from approved drugs like Resmetirom and OCA will influence pricing strategies.

FAQs

1. What is the current clinical stage of NDC 23155-0600?
   It is in late-stage Phase 3 trials, with data expected in Q4 2023.

2. What is the typical pricing range for NASH therapies?
   Between $15,000 and $20,000 annually per patient.

3. When could the drug realistically reach the market?
   Possibly in 2024, contingent on successful trial outcomes and regulatory approval.

4. Who are the main competitors?
   Resmetirom (MGL-3196) and Obeticholic Acid are leading competitors with approved or near-approved therapies.

5. What factors could influence pricing and market penetration?
   Clinical efficacy, safety profile, regulatory approval speed, payer negotiations, and competitive offerings.

---

Sources

1. Chalasani, N., Younossi, Z., Lavine, J. E., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328-357.
2. MarketWatch. (2023). NASH therapeutics market size and forecast. Retrieved from marketwatch.com
3. IQVIA. (2022). The Global Use of Medicine—2022 Report.
4. Madrigal Pharmaceuticals. (2023). Clinical trial updates. Retrieved from madrigalpharma.com
5. EvaluatePharma. (2023). World Preview 2023, Outlook to 2028.

---